CompletedNot Applicable

Early Administration of Heparin At FMC for PPCI of STEMI Patients

China1,145 participantsStarted 2022-07-20

Plain-language summary

Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could increase the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI Exclusion Criteria: * Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of CABG; On Coagulation drugs; CPR before randomization; Pregnant or lactating woman.

What they're measuring

The TIMI 3 flow of the infarct related artery before PPCI

Timeframe: Coronary angiography, before PPCI，anticipated within 2 hours after randomization

Trial details

NCT IDNCT05329155

SponsorRenmin Hospital of Wuhan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-20

View on ClinicalTrials.gov More STEMI trials